Abstract 1730P
Background
A constellation of a large attack surface of interconnected devices and cyberimmaturity renders healthcare ripe to cybercrime. These vulnerabilities and their consequences will be magnified by the exponential growth in artificial intelligence. We assess the impact and implications of a cyberattack on a national cancer centre.
Methods
On 14 May 2021 (day 0), the first national healthcare ransomware attack occurred within which all hospitals including Cork University Hospital (CUH) Cancer Centre was implicated. Contingency plans were only present in laboratory services who had previously experience information technology (IT) failures. Departmental handwritten logs of activity and responses for 700 days after the attack were reviewed.
Results
Following the attack, all IT systems were shut down. No hospital cyberattack emergency plan was in place. Within CUH, on day 0, all radiotherapy (RT) treatment stopped, outpatient activity fell by 50%, and elective surgery stopped. Haematology, biochemistry and radiology capacity fell by 90% (daily sample deficit (DSD) 2700 samples), 75% (DSD 2,250 samples), and 90% (100% mammography/PETscan) respectively. Histopathology reporting times doubled (7 to 15 days). or paused IT links. Outsourcing of radiology and radiotherapy (RT) commenced, alternative communication networks (e.g., proton mail; Siilo) were utilised and national conference calls for RT and clinical trials were established. 136 patients had interrupted RT: median gap day 6 days category 1, 10 days for remaining patients. By day 28, e-mail communication was restored. By day 210, reporting and data storage backlogs were cleared and over 2000 computers were checked/replaced by the Irish Army. Notification of patients and staff whose data was compromised is ongoing (day 720).
Conclusions
Cyberattacks have rapid, profound and protracted impacts. While laboratory and diagnostic deficits were readily quantified, the impact of disrupted/delayed care on patient outcomes is less readily quantifiable but likely to be much greater. As criminals and nation states weaponize the internet, cyberawareness and cyberattack plans need to be embedded in healthcare.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
R.J. Keogh: Financial Interests, Other, Travel, Accommodations, Expenses: MSD. All other authors have declared no conflicts of interest.
Resources from the same session
1757P - A real-world evaluation of the effectiveness of thermogram along with clinical breast examination in community-based breast cancer screening program
Presenter: Rahul Ravind
Session: Poster session 23
1758P - Body composition meets precision medicine: The prognostic value of sarcopenia in patients (pt) treated with Molecularly Targeted Agents (MTA)
Presenter: Cinta Hierro
Session: Poster session 23
1760P - Systematic review of quality of life (QoL) inclusion among endpoints, reporting and impact of QoL results in phase III non-inferiority trials of systemic treatments in oncology
Presenter: Jessica Paparo
Session: Poster session 23
1761P - Incidence of herpes zoster in cancer patients in Europe: A systematic review
Presenter: Inga Posiuniene
Session: Poster session 23
1762P - Are published data up-to-date? Analysis of time to publication in major oncological journals
Presenter: Pawel Sobczuk
Session: Poster session 23
1763P - The challenge for Cancer Trials Ireland (CTI) to sponsor NCI and non-EU sponsored trials in the EU
Presenter: Eibhlin Mulroe
Session: Poster session 23
1886P - Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)
Presenter: Craig Gedye
Session: Poster session 23
1887P - Adjuvant everolimus (EVE) in patients (pts) with completely resected very high-risk renal cell cancer (RCC) and clear cell histology: Results from the phase III SWOG S0931 (EVEREST) trial
Presenter: Primo Lara
Session: Poster session 23
1888P - 24-month follow up of durvalumab and savolitinib combination in MET-driven clear cell and non-clear cell renal cancer
Presenter: Francesca Jackson-Spence
Session: Poster session 23